VUB spin-off Precirix, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and the Institute for Energy Technology (IFE), a manufacturer of radiopharmaceutical products based in Norway, announced an agreement for the supply of Precirix’ radiopharmaceuticals in Europe.
The agreement with IFE will provide long-term clinical trial supply of Precirix’ product candidates that combine camelid-derived single-domain antibodies with Iodine-131. Technology transfer and manufacturing setup will commence in the following weeks.
